Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Recent & Breaking News (OTCQB:PVCT)

Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

GlobeNewswire June 1, 2020

Provectus Announces Publication of Updated Data from Metastatic Neuroendocrine Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

GlobeNewswire June 1, 2020

Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II

GlobeNewswire May 18, 2020

Provectus Announces Acceptance of PV-10® Liver Cancer Abstracts at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

GlobeNewswire April 29, 2020

Provectus Announces PV-10® Liver Cancer Presentation in ePoster Gallery of Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting

GlobeNewswire April 16, 2020

PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020

GlobeNewswire March 17, 2020

Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019

GlobeNewswire December 12, 2019

Provectus Announces PV-10® Abstract Accepted for Presentation at Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting

GlobeNewswire December 2, 2019

Provectus Announces Presentation of Initial Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Refractory Advanced Melanoma at SMR 2019 Congress

GlobeNewswire November 21, 2019

Provectus Announces Presentation of Updated Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Naïve Advanced Melanoma at SMR 2019 Congress

GlobeNewswire November 21, 2019

Provectus Announces Acceptance of PV-10® Poster Presentations at ESMO Immuno-Oncology Congress 2019

GlobeNewswire October 24, 2019

Provectus Announces Acceptance of PV-10 Poster Presentations at SMR 2019 Congress

GlobeNewswire September 24, 2019

Provectus Names Harold Schmitz, PhD to Company's Scientific Advisory Board

GlobeNewswire September 11, 2019

PV-10-based Cancer Combination Therapy Clinical Trial Design Wins Australasian Gastro-Intestinal Trials Group's New Concepts Award

GlobeNewswire August 27, 2019

Provectus Names Frank Akers, PhD to Company's Strategic Advisory Board

GlobeNewswire July 29, 2019

Provectus Receives Notice of Allowance for Fourth Cancer Combination Therapy Patent from the United States Patent and Trademark Office

GlobeNewswire July 15, 2019

Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10

GlobeNewswire July 8, 2019

Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019

GlobeNewswire June 3, 2019

Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019

GlobeNewswire June 3, 2019

Provectus Appoints Bruce Horowitz as Chief Operating Officer

GlobeNewswire May 9, 2019